Butorphanol tartrate is a synthetic opioid pain reliever that works differently from most opioids. It activates some of the brain’s pain-relief pathways while partially blocking others, which gives it a unique profile: effective pain control with a lower risk of the severe breathing problems that make traditional opioids dangerous. It’s classified as a Schedule IV controlled substance in the United States, meaning it has a recognized medical use and a relatively lower potential for abuse compared to stronger opioids like morphine or oxycodone. You may encounter it under brand names like Stadol (for humans) or Torbugesic and Torbutrol (for animals).
How Butorphanol Works
Most opioid painkillers fully activate the mu opioid receptor, the brain’s primary pain-dimming switch. Butorphanol only partially activates that receptor while also acting on a second receptor called the kappa receptor. This dual action means it relieves moderate to severe pain effectively but hits a ceiling on some of the riskier opioid effects. In studies comparing equal doses, 2 mg of butorphanol given intravenously depressed breathing to about the same degree as 10 mg of morphine, but beyond a certain dose, butorphanol’s respiratory effects plateau rather than continuing to worsen.
Because butorphanol partially blocks the mu receptor, it can actually reduce or reverse the effects of other opioids. This is important if you’re already taking a full opioid painkiller, because adding butorphanol could trigger withdrawal symptoms or reduce the other drug’s effectiveness.
Medical Uses in Humans
Butorphanol is approved for two main purposes: treating moderate to severe pain and managing migraine headaches. For pain, it’s given by injection (into a vein or muscle), often in surgical settings or as a supplement to general anesthesia. For migraines, it’s available as a nasal spray, which makes it practical for use at home without needles.
The nasal spray delivers 1 mg per spray. A typical starting dose is one spray in one nostril, with a second dose allowed after 60 to 90 minutes if the pain hasn’t eased enough. For severe pain, some patients use one spray in each nostril (2 mg total) as an initial dose, though this higher dose is more likely to cause drowsiness or dizziness. Pain relief begins within about 15 minutes of using the spray, peaks at 1 to 2 hours, and lasts 4 to 5 hours, which is longer than the injectable form.
Veterinary Uses
If you came across butorphanol tartrate on a vet bill, that’s because it’s widely used in animal medicine. In horses, it’s a go-to treatment for colic pain, including pain from intestinal twisting, impaction, and spasms. Intravenous doses in horses provide relief for at least 4 hours.
In dogs and cats, butorphanol serves double duty as both a painkiller and a cough suppressant. Its antitussive activity is 15 to 20 times stronger than codeine or dextromethorphan in dogs. Veterinarians also value it because it causes minimal effects on the heart and lungs in animals, making it a safer sedation option for procedures.
Common Side Effects
The most frequent side effects in humans are drowsiness, dizziness, nausea, and vomiting. Drowsiness is particularly common with the nasal spray at higher doses, which is why patients using the 2 mg starting dose are advised to lie down afterward.
Less commonly, butorphanol can cause difficulty breathing. In overdose situations, symptoms include extremely slow or shallow breathing, irregular heartbeat, and loss of consciousness. Because of its ceiling effect on respiratory depression, overdose is less likely to be fatal than with full opioid agonists, but the risk is still real, especially when combined with alcohol, benzodiazepines, or other sedating drugs.
Pregnancy and Breastfeeding
Butorphanol crosses into breast milk, though in small amounts. At a typical dose of 2 mg given by injection four times daily, the estimated concentration in milk is about 4 micrograms per liter, which is considered clinically insignificant. The drug is also poorly absorbed through the infant’s gut, further reducing the risk. Still, nursing parents should watch for signs of excess sleepiness, limpness, difficulty feeding, or breathing changes in the infant.
When used as labor pain medication, butorphanol may delay the start of breastfeeding. One study found that women who received butorphanol during labor took about 46 minutes to achieve effective breastfeeding, compared to 35 minutes for women who received no pain medication. A larger survey found that women who received any labor pain medication had roughly twice the risk of a delay in their milk fully coming in (beyond 72 hours postpartum).
Who Should Avoid It
Because butorphanol partially blocks opioid receptors, anyone currently dependent on a full opioid painkiller risks withdrawal symptoms if they take it. This includes people on long-term pain management with drugs like oxycodone, hydrocodone, or morphine. The antagonist activity can abruptly reverse the effects of those medications, causing agitation, sweating, cramping, and other withdrawal signs.
People with significant respiratory conditions should also use butorphanol cautiously, since even its limited breathing suppression could be enough to cause problems in someone whose baseline lung function is already compromised. Combining it with alcohol, sedatives, or other central nervous system depressants amplifies drowsiness and breathing risks considerably.